ARTICLE | Company News
BioSante deal
September 19, 2005 7:00 AM UTC
BPA granted an undisclosed European pharmaceutical company an exclusive option to license BPA's calcium phosphate nanotechnology (CaP) to develop allergy products. BPA said it will receive a $250,000 ...